Pharmaceuticals News and Research

RSS

Armetheon reaches agreement with FDA on SPA for final pivotal trial of tecarfarin

Armetheon, Inc., today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the final pivotal trial of tecarfarin.

29 Apr 2014

First Edition: April 29, 2014

Today's headlines include a report that the Obama administration is looking for new talent to run healthcare.gov.

29 Apr 2014

Adhesion molecule offers promising therapeutic target for preventing colitis

May Provide Therapeutic Target for Treating Inflammatory Bowel Disease and Preventing Colitis-Associated Colorectal Cancer, According to New Research Published in The American Journal of Pathology

29 Apr 2014

Magellan Health Services reports net revenue of $966.5 million for first quarter 2014

Magellan Health Services, Inc. today reported financial results for the first quarter 2014, as summarized below. For the quarter ended March 31, 2014, the company reported net revenue of $966.5 million, segment profit of $76.5 million, and net income of $25.7 million, or $0.92 earnings per share (EPS).

29 Apr 2014

Teva's DuoResp Spiromax receives EC marketing authorization for treatment of asthma, COPD

Teva Pharmaceutical Industries Ltd., announced today that the European Commission has granted marketing authorization for DuoResp Spiromax for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD) where the use of a combination of an inhaled corticosteroid and long-acting beta2-adrenoceptor agonist is appropriate.

29 Apr 2014

Columbia Laboratories' total revenues increase 15% to $7.2 million in first quarter 2014

Columbia Laboratories, Inc. today announced financial results for the three-month period ended March 31, 2014.

29 Apr 2014

Actavis' subsidiary files lawsuit against FDA over Celebrex decision

Actavis plc today announced that its subsidiary, Watson Laboratories, Inc., has filed suit against the U.S. Food and Drug Administration challenging the Agency's decision regarding its entitlement to shared 180-day marketing exclusivity for its generic version of Celebrex (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules.

29 Apr 2014

Civitas reports positive results from CVT-301 Phase 2b trial for treatment of Parkinson's disease

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing and commercializing transformative therapeutics using its proprietary ARCUSTM technology, today announced positive results from a Phase 2b clinical trial of CVT-301, an inhaled formulation of levodopa (L-dopa).

29 Apr 2014

Highland subsidiary begins enrolment in Phase III study of HLD-200 in pediatric ADHD patients

Highland Therapeutics Inc., an emerging pharmaceutical company, today announced that its wholly owned subsidiary has begun enrolment in a Phase III study of HLD-200, the Company's novel formulation of methylphenidate, in pediatric patients with Attention-Deficit Hyperactivity Disorder ("ADHD").

28 Apr 2014

Emilia Group completes acquisition of Pharma Pac's strategic assets

Emilia Group is pleased to announce the recent acquisition of strategic assets of Pharma Pac LLC, an OTC private brand and contract manufacturer, located in DeKalb, MS. The new entity is named Emilia Resources LLC and will operate as a manufacturing company of pharmaceutical and cosmetic products that will combine with Emilia Personal Care's strength in sales, marketing, supply chain and customer service.

28 Apr 2014

Forest Laboratories enters into definitive agreement to acquire Furiex

Forest Laboratories, Inc. nd Furiex Pharmaceuticals, Inc. today announced that Forest has entered into a definitive agreement to acquire Furiex, a drug development collaboration company, for $95 per share, or approximately $1.1 billion in cash, and up to $30 per share (approximately $360 million in aggregate) in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

28 Apr 2014

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia and Alimera Sciences.

28 Apr 2014

Agenus enters into agreement with Merck for development of therapeutic antibodies

Agenus Inc. announced today that the company has entered into a collaboration and license agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, for the discovery and development of therapeutic antibodies to immune checkpoints for the treatment of cancer. Under the terms of the agreement, Agenus will discover and optimize fully human antibodies against two undisclosed Merck checkpoint targets using the 4-Antibody Retrocyte Display® platform.

28 Apr 2014

Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China that focuses on the research, development, manufacturing and commercialization of vaccines, announced today that it has entered into a license agreement with Intravacc (Institute for Translational Vaccinology) from The Netherlands to develop and commercialize the Sabin Inactivated Polio Vaccine (sIPV) for distribution to China and other countries.

28 Apr 2014

APCER Pharma's revenues grew by more than 40% in 2013

APCER Pharma, the truly global provider of strategic and outsourced services for clinical safety, pharmacovigilance, medical affairs, and regulatory operations, announced today that revenues grew by more than 40% in 2013 compared to the previous year.

28 Apr 2014

Genervon completes GM604 Phase 2a clinical trial for amyotrophic lateral sclerosis

Genervon Biopharmaceuticals LLC today announced that it has successfully completed its Phase 2a clinical trial for amyotrophic lateral sclerosis ("ALS") disease modification. A full analysis of the trial's results is expected to be completed in the third quarter of 2014, but preliminary data suggests that Genervon's novel, proprietary, multi-target biological drug candidate, GM604, shows significant promise for treating ALS.

28 Apr 2014

Researchers analyze patient satisfaction with pain treatment after surgery

An international research group with members from the University of Basel, several EU countries, Israel and the USA, analyzed patient satisfaction with pain treatment after surgery.

28 Apr 2014

H2Ocean launches Extreme Tattoo Aftercare Kit

H2Ocean, a leader in developing natural health care products using patented sea salt formulas, is proud to announce the launch of their coveted Extreme Tattoo Aftercare Kit in 5,179 Walgreens stores Nationwide found in the First Aid Section.

26 Apr 2014

New data from EMD Serono's multiple sclerosis portfolio to be presented at the 66th AAN Annual Meeting

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the company's multiple sclerosis (MS) portfolio will be presented at the American Academy of Neurology's 66th Annual Meeting, taking place from April 26 – May 3, in Philadelphia, PA.

26 Apr 2014

Study finds role of oligomers in development of Parkinson's disease

Researchers at Aarhus University, Denmark, have drawn up the most detailed 'image of the enemy' to date of one of the body's most important players in the development of Parkinson's disease.

26 Apr 2014

Pharmaceuticals News and Research

Armetheon reaches agreement with FDA on SPA for final pivotal trial of tecarfarin

First Edition: April 29, 2014

Adhesion molecule offers promising therapeutic target for preventing colitis

Magellan Health Services reports net revenue of $966.5 million for first quarter 2014

Teva's DuoResp Spiromax receives EC marketing authorization for treatment of asthma, COPD

Columbia Laboratories' total revenues increase 15% to $7.2 million in first quarter 2014

Actavis' subsidiary files lawsuit against FDA over Celebrex decision

Civitas reports positive results from CVT-301 Phase 2b trial for treatment of Parkinson's disease

Highland subsidiary begins enrolment in Phase III study of HLD-200 in pediatric ADHD patients

Emilia Group completes acquisition of Pharma Pac's strategic assets

Forest Laboratories enters into definitive agreement to acquire Furiex

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Agenus enters into agreement with Merck for development of therapeutic antibodies

Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

APCER Pharma's revenues grew by more than 40% in 2013

Genervon completes GM604 Phase 2a clinical trial for amyotrophic lateral sclerosis

Researchers analyze patient satisfaction with pain treatment after surgery

H2Ocean launches Extreme Tattoo Aftercare Kit

New data from EMD Serono's multiple sclerosis portfolio to be presented at the 66th AAN Annual Meeting

Study finds role of oligomers in development of Parkinson's disease

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence